Exploring AstraZeneca's Potential Spin-Off of China Business

This chapter examines AstraZeneca's potential spin-off of its China business in light of US-China tensions. It highlights the broader implications for the pharmaceutical industry in China, focusing on the lucrative market opportunities presented by an aging population and rising chronic diseases.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app